24 completed, 7 unknown, 3 recruiting, 2 withdrawn. 17 Phase 2, 12 Phase 3, 7 Phase 1, 4 Phase 4.
Follow mRNA-1273: new trials by email Literature Review of mRNA-1273 trials Research Report on mRNA-1273
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations mRNA-1273, mRNA-1283 - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 300 | 2026-10-09 | 2026-10-27 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age mRNA-1283, mRNA-1273 - SARS-CoV-2 | Phase 2 | Recruiting | ModernaTX, Inc. | 300 | 2026-09-04 | 2026-10-29 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) mRNA-1273, mRNA-1283, Placebo - SARS-CoV-2 | Phase 4 | Active not recruiting | ModernaTX, Inc. | 30000 | 2025-11-26 | 2026-09-28 |
| Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age mRNA-1083, Placebo, Licensed Influenza Vaccine - COVID-19, Influenza | Phase 3 | Completed | ModernaTX, Inc. | 2457 | 2024-11-18 | 2025-12-02 |
| Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose - COVID-19 | Phase 3 | Withdrawn | Murdoch Childrens Research Institute | 2024-04-01 | 2024-03-22 | |
| A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine mRNA-1273 - Myocarditis, Pericarditis | Completed | ModernaTX, Inc. | 1169 | 2023-03-31 | 2025-08-01 | |
| A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years SCTV01E, mRNA-1273 - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 300 | 2022-07-01 | 2022-04-26 |
| A Study of Modified mRNA Vaccines in Healthy Adults mRNA-1273, mRNA-1010, mRNA-1345 - SARS-CoV-2, Seasonal Influenza | Phase 1 | Completed | ModernaTX, Inc. | 308 | 2022-05-24 | 2026-03-12 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old mRNA-1073, mRNA-1010, mRNA-1273 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 550 | 2022-05-13 | 2024-02-28 |
| Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose - COVID-19 | Phase 3 | Terminated | Murdoch Childrens Research Institute | 13 | 2022-05-02 | 2024-12-16 |
| Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine solid microneedle skin patch, mRNA-1273, standard needle - Vaccination; Infection, COVID-19 | Phase 2 | Unknown | Leiden University Medical Center | 20 | 2022-05-01 | 2022-04-22 |
| COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) AS03, BNT162b2, BNT162b2 (B.1.1.529) - COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1270 | 2022-03-30 | 2025-10-20 |
| A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 mRNA-1273.529, mRNA-1273, mRNA-1273.214 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 3548 | 2022-02-16 | 2024-08-09 |
| Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) V110, V114, mRNA-1273 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 850 | 2022-01-12 | 2025-07-18 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters mRNA-1283, mRNA-1283.211, mRNA-1273 - SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 540 | 2021-12-06 | 2025-07-17 |
| The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 340 | 2021-11-30 | 2022-07-25 |
| RECOVAC Repeated Vaccination Study mRNA-1273, Ad26.COV2.S vaccine - Covid19, Kidney Diseases | Phase 4 | Completed | University Medical Center Groningen | 336 | 2021-10-21 | 2022-03-29 |
| A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine HZ/su, Flu D-QIV, mRNA-1273 - Herpes Zoster | Phase 3 | Completed | GlaxoSmithKline | 2013 | 2021-10-07 | 2023-11-13 |
| COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients mRNA-1273 - Covid19, SARS-CoV2 Infection | Completed | H. Lee Moffitt Cancer Center and Research Institute | 336 | 2021-09-10 | 2023-04-14 | |
| Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination MRNA-1273 - Covid19 | Phase 2 | Withdrawn | Maria Joyera Rodríguez | 2021-09-01 | 2025-06-22 |
Showing 20 of 38. Sign in to see all of them.
COVID-19 (35) · Coronavirus Infections (14) · Virus Diseases (10) · Influenza, Human (4) · Autoimmune Diseases (1) · Breakthrough Infections (1) · Cytomegalovirus Infections (1) · Drug-Related Side Effects and Adverse Reactions (1) · Hematologic Neoplasms (1) · Herpes Zoster (1) · Hypersensitivity (1) · Infections (1) · Kidney Diseases (1) · Leukemia (1) · Long Term Adverse Effects (1)
ModernaTX, Inc. (15) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Murdoch Childrens Research Institute (2) · Assistance Publique - Hôpitaux de Paris (1) · Chang Gung Memorial Hospital (1) · GlaxoSmithKline (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Leiden University Medical Center (1) · Maria Joyera Rodríguez (1) · Masaryk University (1) · Mebo Research, Inc. (1) · Medical University of Vienna (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1)
United States (24) · Germany (3) · United Kingdom (3) · Canada (2) · Dominican Republic (2) · Mexico (2) · Netherlands (2) · Puerto Rico (2) · Taiwan (2) · Argentina (1) · Australia (1) · Austria (1) · Croatia (1) · Czechia (1) · Denmark (1)
Anna Giuliano, PhD (1) · Anna H Roukens, MD PhD (1) · Audrey Pettifor (1) · Cheng-Hsun Chiu, MD, PhD (1) · Eddy Fadlyana, Dr (1) · Irene Gabashvili, PhD (1) · James Gulley, M.D. (1) · James R. Baker Jr., MD (1) · Jan-Stephan F Sanders, MD PhD (1) · Jasmine Marcelin (1) · Kathryn Stephenson (1) · Kim Mulholland, MD (1) · Kirsten E Lyke, M.D. (1)
PMID 35547849, PMID 32663912, PMID 32991794, PMID 33378609, PMID 34090865, PMID 34360156, PMID 34379915, PMID 34401888, PMID 34551225, PMID 34642699, PMID 34870630, PMID 35072628, PMID 35081293, PMID 35126362, PMID 35145311, PMID 35291289, PMID 35535503, PMID 35544369, PMID 35785530, PMID 35798000, PMID 35898343, PMID 36055877, PMID 36112399, PMID 36202997, PMID 36238717, PMID 36260859, PMID 36309347, PMID 36354032, PMID 36381503, PMID 36399969, PMID 37074202, PMID 37075127, PMID 37205592, PMID 37330602, PMID 37335963, PMID 37348519, PMID 37385888, PMID 37433788, PMID 37473964, PMID 37640860, PMID 37653342, PMID 37703353, PMID 37781954, PMID 37992183, PMID 38023544, PMID 38513368, PMID 38513689, PMID 38518789, PMID 38902860, PMID 39158584
5UM1AI148373-05 (2), 2023 (1), 5UM1AI148684-02 (1), 5UM1AI148684-03 (1)